Prevention of dementia should start 20 years before symptoms become apparent

European Heart Journal

Volumn 32, Issue 18, 2011, Pages 2228-2230

  Diener, Hans Christoph ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ALZHEIMER DISEASE; CARDIOVASCULAR RISK; COGNITION; DEMENTIA; DISEASE ASSOCIATION; EDITORIAL; HIGH RISK POPULATION; HUMAN; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; PREVALENCE; PRIORITY JOURNAL; SYMPTOM;

CARDIOVASCULAR DISEASES; COGNITION DISORDERS; FEMALE; HUMANS; MALE;

EID: 80052883992     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr122     Document Type: Editorial

References (13)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-2117. (Pubitemid 41797645)
2. Kuller LH, Lopez OL, Jagust WJ, Becker JT, DeKosky ST, Lyketsos C, Kawas C, Breitner JC, Fitzpatrick A, Dulberg C. Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology 2005;64:1548-1552. (Pubitemid 40617690)
3. Kivipelto M, Solomon A. Alzheimer's disease-the ways of prevention. J Nutr Health Aging 2008;12:89S-94S.
4. Schneider JA, Bennett DA. Where vascular meets neurodegenerative disease. Stroke 2010;41(10 Suppl):S144-S146.
5. Humpel C. Chronic mild cerebrovascular dysfunction as cause for Alzheimer's disease? Exp Gerontol 2011;46:225-232.
6. Kaffashian S, Dugravot A, Nabi H, Batty GD, Brunner E, Kivimäki M, Singh-Manoux A. Predictive utility of the Framingham general cardiovascular disease risk profile for cognitive function: evidence from the Whitehall II study. Eur Heart J 2011;32:2326-2332. First published on 23 May 2011. doi: 10.1093/eurheartj/ehr133.
7. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005;64:277-281.
8. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163:1069-1075. (Pubitemid 36548935)
9. Saxby BK, Harrington F,Wesnes KA, McKeith IG, Ford GA. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. Neurology 2008;70:1858-1866. (Pubitemid 351653953)
10. Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 2008;7:875-884.
11. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, for the PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630. (Pubitemid 35379733)
12. Waters DD. Exploring new indications for statins beyond atherosclerosis: Successes and setbacks. J Cardiol 2010;55:155-162.
13. Forette F, Seux M, Staessen J, Thijs L, Birkenhager W, Babarskiene M, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347-1351. (Pubitemid 28510916)